TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00847626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
Study: NCT05213546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: bicycle ergometer exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: bicycle ergometer exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: bicycle ergometer exercise training
Study: NCT03334253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Daily 0.01% atropine eyedrops

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Eyedrops
Description: Daily placebo eyedrops
Study: NCT00333749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drinking or rinsing the mouth 2-3 times for 1 day

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pasturlized cow milk
Description: Drinking or rinsing the mouth 2-3 times for one day.
Study: NCT00121667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Description: Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Description: Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin + Metformin
Description: Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Metformin
Description: Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Tablets, Oral, 15 - 45 mg (as needed for rescue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15 - 45 mg (as needed for rescue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15 - 45 mg (as needed for rescue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablets, Oral, 15 - 45 mg (as needed for rescue)
Study: NCT01621243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-paclitaxel
Description: nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be dosed daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necuparanib
Description: Necuparanib will be dosed daily
Study: NCT01953445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT00968526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
Study: NCT02935803

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-vaginal Mesh operation
Description: Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trans-vaginal Mesh operation
Description: Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
Study: NCT01948674

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized tasks
Description: The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized tasks
Description: The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
Study: NCT01126034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention letter
Description: Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~1. The name and medical record # of the patients involved~2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~3. A reminder of the adverse effect of long-term metoclopramide therapy~4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~5. A request that the physician document the discontinuation trial in the electronic medical record
Study: NCT04324905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1802
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1802
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Reference drug
Study: NCT04079205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Device(exoRehab)
Description: rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home rehabilitation program
Description: rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
Study: NCT03188367

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Gluten or placebo capsules
Description: Administration of gluten or placebo capsules
Study: NCT02029963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: A non-invasive method for brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (rTMS)
Description: A non-invasive method for brain stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
Study: NCT00915824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPP/START criteria
Description: Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
Study: NCT04420429

Intervention type: PROCEDURE
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Description: All participants underwent DMEK surgery
Study: NCT03142269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 360°anterior capsule polishing
Description: 360°anterior capsule polishing was performed with double-ended capsule polisher

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 360°anterior capsule polishing
Description: 360°anterior capsule polishing was performed with double-ended capsule polisher
Study: NCT04370015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: • Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
Study: NCT03618004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs.
Study: NCT03609268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: microwave ablation (MWA)
Description: microwave ablation (MWA) for recurrent small liver cancer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: stereotactic body radiotherapy (SBRT) for recurrent small liver cancer
Study: NCT00999739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar and Pneumo23
Description: Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar and Pneumo23
Description: Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
Study: NCT04483856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermoRelizema cream
Description: Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexeryl
Description: FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).
Study: NCT02489734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: extubation when end-tidal concentration of sevoflurane \< 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: extubation when end-tidal concentration of sevoflurane \>= 0.5%
Study: NCT01834612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CM1500
Description: blood volume monitor

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CM1500
Description: blood volume monitor
Study: NCT02610075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
Study: NCT02478437

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiofrequency ablation (RFA)
Description: A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency Ablation (CRFA)
Description: Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
Study: NCT00002838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Study: NCT02697396

Intervention type: BEHAVIORAL
Intervention: Assessments
Description: All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.

Intervention type: BEHAVIORAL
Intervention: Assessments
Description: All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.

Intervention type: OTHER
Intervention: Text Message Reminder
Description: Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.

Intervention type: OTHER
Intervention: No Text Messaging
Description: Participants in this arm will receive no additional vaccination reminders.
Study: NCT03516305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Alprazolam 1 mg
Description: alprazolam I mg administered via the Staccato hand-held inhaler device system.
Study: NCT01914081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
Study: NCT00531336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injection of Bevacizumab (Avastin)
Description: 1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injection of Bevacizumab (Avastin)
Description: 1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
Study: NCT02657824

Intervention type: OTHER
Intervention: dyspneic patients
Description: measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
Study: NCT02288481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Description: TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Suspension
Study: NCT01724944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic pelvic and aortic lymphadenectomy
Description: Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
Study: NCT02066727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is administrated as an adjuvant of lidocaine.